Citations

Clear

381 citation(s) found for "Gross, MS".

A harmonized memory composite score for cross‐cohort Alzheimer’s disease and related dementia research: development and validation
Gross, Alden L. , Casaletto, Kaitlin B. , Chatterjee, Ankita , Albert, Marilyn S. , Apostolova, Liana G. , Boersema, Brooke, Boxer, Adam L., Clark, Lindsay R. , Eloyan, Ani , Farias, Sarah Tomaszewski , Hammers, Dustin B. , Wise, Amy B. , Yballa, Claire, Hampstead, Benjamin M. , Rascovsky, Katya, Ringman, John M. , Rosen, Howard J., Salmon, David P. , Kramer, Joel H. , Staffaroni, Adam M. , Sanderson‐Cimino, Mark , Gaynor, Leslie S. , Paolillo, Emily W. , Boxer, Adam L. , Boeve, Bradley F. , Joie, Renaud La , Gonzales, Mitzi M. , Hammers, Dustin B , Cobigo, Yann , Schonhaut, Daniel R. , Mechanic-Hamilton, Dawn J. , Miller, Bruce L. , Rabinovici, Gil D. , Ryman, Sephira G. , Smith, Glenn E. , DeCarli, Charles

Mayo Clinic

Alzheimer's & Dementia | January 3, 2025 | Volume: 20 | Issue: S3 | Pages: No page available

10.1002/alz.093383 Get It

AbstractBackgroundThe Uniform Data Set (UDS) neuropsychological battery, administered across Alzheimer’s Disease Centers (ADC), includes memory tests but lacks a list‐learning paradigm. ADCs often supplement the UDS with their own preferred list‐learning task. Given the importance of list‐learning for characterizing memory, we aimed to develop a harmonized memory score that incorporates UDS memory tests while allowing centers to contribute differing list‐learning tasks.MethodWe applied item‐banking confirmatory factor analysis to develop a composite memory score in 5,287 participants (mean age 67.1; SD = 12.2) recruited through 18 ADCs and four consortia (DiverseVCID, MarkVCID, ALLFTD, LEADS) who completed UDS memory tasks (used as linking‐items) and one of five list‐learning tasks. All analyses used linear regression. We tested whether memory scores were affected by which list‐learning task was administered. To assess construct validity, we tested associations of memory scores with demographics, disease severity (CDR Box Score), an independent memory task (TabCAT Favorites, n = 675), and hippocampal volume (n = 811). We compared performances between cognitively unimpaired (n = 279), AD‐biomarker+ MCI (n = 26), and AD‐biomarker+ dementia (n = 98). In a subsample with amyloid‐ and tau‐PET (n = 49), we compared memory scores from participants with positive vs negative scans determined using established quantitative cutoffs.ResultModel fit indices were excellent (e.g., CFI = 0.998) and factor loadings were strong (0.43‐0.93). Differences in list‐learning task had a negligible effect on scores (average Cohen’s d = 0.11). Higher memory scores were significantly (p’s<.001) correlated with younger age (β = ‐0.18), lower CDR Box Scores (β = ‐0.63), female sex (β = 0.12), higher education (β = 0.19), larger hippocampal volume (β = 0.42), and an independent memory task (β = 0.71, p<0.001). The memory composite declined in a stepwise fashion by diagnosis (cognitively unimpaired>MCI>AD dementia, p<0.001). On average, amyloid‐PET positivity was associated with lower composite scores, but was not statistically significant (β = ‐0.34; p = 0.25; d = 0.40). Tau‐PET positivity was associated with worse performance, demonstrating a large effect size (β = ‐0.75; p<0.002; d = 0.91).ConclusionThe harmonized memory score developed in a large national sample was stable regardless of contributing list‐learning task and its validity for cross‐cohort ADRD research is supported by expected associations with demographics, clinical measures, and Alzheimer’s biomarkers. A processing script will be made available to enhance cross‐cohort ADRD research.
(230) EXPLORING HOW BMI SHAPES THE SUCCESS OF INFLATABLE PENILE PROSTHESIS SURGERY: MULTI-CENTER STUDY INSIGHTS
Hammad, Muhammed , Gross, MS, Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Modgil, Vaibhav , Perito, P, Hotaling, JM, Park, SH, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Renterghem, Katrien Van, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Karthikeyan, Hridhay, Simhan, J, Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed A M , Miller, John D. , Chawareb, Elia Abou , Amini, Erfan , Hatzichristodoulou, Georgios , Osmonov, D, Perito, P, Suarez‐Sarmiento, Alfredo, Azad, Babak Kazemzadeh , Jenkins, Lawrence C. , Jones, James M. , Simhan, Jay , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | December 11, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.224 Get It

Abstract Introduction Obesity, defined as an elevated Body Mass Index (BMI) &gt;30, is a prevalent public health concern with far-reaching implications for various medical procedures and outcomes. In the context of inflatable penile prosthesis placement (IPP), where patient well-being and surgical success are of paramount importance, the impact of obesity on postoperative and intraoperative complications warrants thorough investigation. Objective We aimed to investigate the impact of BMI on both postoperative and intraoperative complications in an international, multi-institutional cohort of patients who underwent IPP placement. Methods We performed a retrospective chart review of 4,398 cases. These cases were divided into two distinct groups based on BMI: less than 30 (n = 2,260) and greater than or equal to 30 (n = 2,138). The study assessed various surgical factors as well as complications, including overall complications, corporal scarring, incontinence, intraoperative complications, proximal perforation, distal perforation, proximal crossover, distal crossover, and urethral injury. Results Our analysis revealed that there were no statistically significant differences in intraoperative or postoperative complications between the two BMI categories. Notably, proximal corporal measurement was significantly higher for &gt;30 BMI group with 1858 (86.9%) compared to 1919 (84.9%) for &lt;30 BMI group, (p = &lt; 0.001). The incidence rates for overall complications (30.2% vs. 28.7%; p = 0.164), corporal scarring (18.2% vs. 16.7%; p = 0.36), incontinence (3.53% vs. 3.13%; p = 0.076), intraoperative complications (1.94% vs. 1.68%; p = 0.253), and specific complications all exhibited no significant differences. Similarly, post-operative complications, including both non-infectious (6.99% vs. 6.22%; p = 0.215) and infectious (2.61% vs. 1.87%; p = 0.165) complications, did not significantly vary between BMI categories. Conclusions Our findings indicate that BMI does not exert a statistically significant influence on postoperative and intraoperative complications in the context of high-volume prosthetic urology. In the absence of any other differences between patients of differing BMIs, the IPP industry may need to consider device specific alterations with pump tubing length in obese patients. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
(165) NOVEL INSIGHTS ON PERIOPERATIVE ANTIMICROBIAL PROPHYLAXIS PATTERNS FOR INFLATABLE PENILE PROSTHESIS: FINDINGS FROM A LARGE MULTINATIONAL COLLABORATIVE
Hammad, MAM, Gross, MS, Swerdloff, Daniel , Miller, Justin , Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Osmonov, Daniar , Jones, Adam , Modgil, Vaibhav , Perito, P, Hotaling, JM, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Simhan, Jay , Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed , Hammad, Muhammed A M , Azad, Babak Kazemzadeh , Chawareb, Elia Abou , Hatzichristodoulou, Georgios , Park, SH, Suarez‐Sarmiento, Alfredo, Renterghem, Koenraad van , Jenkins, Lawrence C. , Jones, James M. , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | December 11, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.162 Get It

Abstract Introduction Inflatable penile prosthesis (IPP) surgery is a well-established treatment for erectile dysfunction (ED). There is little information in the literature regarding the utilization of perioperative antimicrobial prophylaxis in primary and revision IPP surgeries. Objective We investigated the patterns of perioperative antimicrobial prophylaxis among a large multinational cohort of primary and revision IPP surgeries. Methods We conducted a retrospective analysis of 5,400 patients (4,187 primary IPP patients and 849 revision IPP patients) from our Prosthetic Urology Multi-Institutional Partnership (PUMP) institutions. Usage data for intravenous (IV), preoperative oral, and postoperative oral antimicrobials were analyzed. We specifically assessed patient profiles, antimicrobial selection, and antimicrobial duration. Multivariate statistical analyses were conducted to identify significant variations between primary and revision surgeries. Results For patients undergoing primary IPP placement, 81.9% received IV antibiotics for &lt;24 hours whereas 18.1% received IV antibiotics for &gt;24 hours. Preoperative oral antimicrobials were used in 59.4% of patients and 99.4% received postoperative oral antimicrobials. The overall infection rate for primary implants was 2%. Notably, quinolone administration shows a higher postoperative infection rate (11.4%) compared to gentamicin (1.9%), cephalosporin (0%), and vancomycin (1.0%). Multivariable regression analysis identifies factors such as a history of infection, diabetes, and priapism as predictors for postoperative infections. Furthermore, the study finds that perioperative antifungal use is associated with a decreased risk of infection. Conclusions This study provides valuable insights into the patterns of perioperative antimicrobial prophylaxis. Duration, type, and route of antibiotics given preoperatively or postoperatively do not affect postoperative infection rates among high volume prosthetic urologists. Giving IV antibiotics for more than 24 hours does not affect postoperative infection. Perioperative antifungals are a protective factor. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
(012) USE OF REAR TIP EXTENDERS IS ASSOCIATED WITH INCREASED RISK OF POST-OPERATIVE COMPLICATIONS AND PENILE PROSTHESIS REVISION IN PATIENTS UNDERGOING PRIMARY INFLATABLE PENILE PROSTHESIS PLACEMENT: RESULTS FROM A LARGE MULTI-INSTITUTIONAL COLLABORATIVE
Dalimov, Zafardjan , Ivan, SJ, Barham, David , Sadeghi‐Nejad, Hossein , Modgi, V, Andrianne, Robert, Sempels, Maxime, Hsieh, Tung‐Chin , Hatzichristodoulou, Georgios , Osmonov, Daniar , Lentz, A, Perito, Paul , Hotaling, James M. , Park, SH, Ziegelmann, Matthew , Pearce, Ian , Gross, MS, Yafi, FA, Simhan, J, Hammad, Muhammed , Hammad, Muhammed A M , Ivan, SJ, Hammad, M, Lentz, A, Renterghem, Koenraad van , Simhan, Jay

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_7 | Pages: No page available

10.1093/jsxmed/qdae167.010 Get It

Abstract Introduction The utilization of rear tip extenders (RTE) is often imperative during Inflatable Penile Prosthesis (IPP) placement. The impact of RTE on perioperative morbidity of IPP surgery is underexplored. Objective In this study, we assess intraoperative and postoperative outcomes among patients undergoing primary IPP implantation with or without RTE. Methods We performed a multicenter, retrospective analysis of men undergoing primary IPP placement between July 2016 and July 2021. A total of 4308 patients were identified, of which 2963 had no RTE and 1345 had RTE. After 1:1 propensity score matching for all confounding variables, 840 patients without RTE were compared to patients with RTE for intraoperative and postoperative outcomes. Chi-square and Mann–Whitney tests were used for statistical analysis for categorial and continuous variables respectively. For multivariable analysis, we used a forward stepwise model and included significant variables found on preoperative characteristics of patients. Kaplan–Meier time to event analysis were compared with Mantel-Cox log-rank test. Results Patients with RTE use had more postoperative complications (9.6% vs 5.2%, p &lt; 0.001). More specifically, RTE patients had more episodes of postoperative hematoma and bleeding (2.0% vs 0.7%, p = 0.033), device malfunction (2.7% vs 1.8%, p = 0.006), and glans-related complications (0.8% vs 0, p = 0.015). On multivariable analysis, use of RTE (OR 1.58, 95% CI 1.07-2.34, p = 0.021), AMS 700 series device (OR 1.93, 95% CI 1.27-2.94, p = 0.002), penoscrotal approach (OR 2.60, 95% CI 1.61-4.18, p &lt; 0.001), and older age (OR 1.02, 95% CI 1.00-1.04, p = 0.035) were associated with increased risk of postoperative complications. Patients with RTE use had increased rate of postoperative IPP revision (5.0% vs 2.1%, p = 0.002). The use of RTE (OR 1.71, 95% CI 1.00-2.90, p = 0.046), AMS 700 series device (OR 1.73, 95% CI 1.01-2.97, p = 0.048), penoscrotal approach (OR 3.16, 95% CI 1.63-6.17, p &lt; 0.001), and history of Peyronie’s disease (OR 2.24, 95% CI 1.31-3.82, p = 0.003) were associated with increased risk of postoperative IPP revision or explantation. On Kaplan–Meier analysis, use of RTE was associated with increased risk of postoperative complications and IPP revision or explantation within 48 months (log rank p = 0.001 and p = 0.002 respectively). Conclusions In this large multi-institutional cohort, patients with RTE experienced more hematoma, device malfunctioning, and glans related post operative complications. The use of RTE is an independent predictor of post-operative complications and IPP revision or explanation. Disclosure No.
New findings regarding predictors of Poor Corporal Integrity in Penile Implant Recipients: A Multicenter International Invesigation
Chang, Chrystal , Barham, David W. , Dalimov, Zafardjan , Swerdloff, Daniel , Sadeghi‐Nejad, Hossein , Andrianne, Robert, Sempels, Maxime, Hsieh, Tung‐Chin , Hatzichristodoulou, Georgios , Hammad, Muhammed , Lentz, Aaron , Perito, Paul , Suarez‐Sarmiento, Alfredo, Hotaling, James M. , Gross, Kelli, Park, Sung Hun, Warner, Jonathan N. , Ziegelmann, Matthew , Modgil, Vaibhav , Jones, Adam , Pearce, Ian , Gross, Martin , Yafi, Faysal A. , Simhan, Jay , Miller, Jake , Jones, James M , Ziegelmann, Matthew , Yafi, Faysal A , Hammad, Muhammed A M , Osmonov, Daniar , Jones, James M. , Renterghem, Koenraad van , Burnett, Arthur L. “Bud”

Mayo Clinic

BJU International | December 10, 2024 | Volume: 135 | Issue: 3 | Pages: 528-534

10.1111/bju.16607 | PMID 39658322 Get It

Objectives To evaluate the pre‐ and intraoperative variables that impact the integrity of the corporal bodies over time after inflatable penile prosthesis (IPP) placement, as predictors of intraoperative corporal perforation and delayed cylinder complications have not been well characterized. Patients and Methods We retrospectively reviewed a 16‐centre multi‐institutional database of IPP surgeries performed by experienced implanters from 2016 to 2021. Poor corporal integrity (PCI) was defined as intraoperative (iPCI) corporal complications or postoperative (pPCI) corporal complications. Multivariable analysis was performed to identify independent predictors of PCI, iPCI, and pPCI. Primary outcomes included intra‐ and postoperative corporal complications. Results We identified 5153 patients for analysis from 5406 IPP cases, finding 152 (2.95%) cases of PCI. On multivariable analysis, predictors of PCI included revision IPP surgery (odds ratio [OR] 8.16, 95% confidence interval [CI] 5.15–12.92; P < 0.001), sequential dilatation (OR 2.12, 95% CI 1.32–3.39; P = 0.002), coronary artery disease (CAD)/peripheral vascular disease (PVD) (OR 1.81, 95% CI 1.18–2.77; P = 0.006), older age (OR 1.02, 95% CI 1.01–1.04; P = 0.013), and corporal scarring (OR 1.58, 95% CI 1.0–2.5; P = 0.049). Predictors of iPCI included revision IPP surgery (OR 7.34, 95% CI 4.18–12.88; P < 0.001), corporal scarring (OR 2.77, 95% CI 1.64–4.69; P < 0.001), radiation therapy (OR 2.25, 95% CI 1.0–5.04; P = 0.049), and older age (OR 1.03, 95% CI 1.0–1.05; P = 0.025). Revision IPP surgery (OR 7.92, 95% CI 3.69–17.01; P < 0.001), sequential dilatation (OR 3.4, 95% CI 1.61–7.19; P = 0.001), CAD/PVD (OR 2.98, 95% CI 1.56–5.72; P = 0.001), and history of priapism (OR 3.59, 95% CI 1.08–11.99; P = 0.038) were predictive of pPCI. Conclusion Coronary artery disease/PVD, being of older age, having corporal scarring, undergoing IPP revision surgery and sequential dilatation were predictive risk factors for complications associated with PCI. Identifying patients who are at risk of having PCI may improve patient‐specific counselling, consideration of referral to more experienced implanters, and surgical planning to potentially promote longer‐term device viability.
(149) NEW FINDINGS REGARDING PERIOPERATIVE INFLATABLE PENILE PROSTHESIS ANTIMICROBIAL PROPHYLAXIS PATTERNS FROM A LARGE MULTINATIONAL COLLABORATION
Hammad, MAM, Gross, MS, Swerdloff, Daniel , Miller, Justin , Alkhayal, A, Alrabeeah, K, Andrianne, Robert, Burnett, AL, Gross, Kelli, Hatzichristodoulou, G, Lentz, A, Osmonov, Daniar , Jones, Adam , Modgil, Vaibhav , Perito, P, Hotaling, JM, Pearce, Ian , Sadeghi‐Nejad, Hossein , Sempels, Maxime, Suarez-Sarmiento, A, Warner, J, Ziegelmann, Matthew , Hsieh, TC, Simhan, Jay , Yafi, FA, collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW, Hammad, Muhammed , Azad, Babak Kazemzadeh , Chawareb, Elia Abou , Hatzichristodoulou, Georgios , Park, SH, Suarez‐Sarmiento, Alfredo, Renterghem, Koenraad van , Jenkins, Lawrence C. , Jones, James M. , collaborators, on behalf of the PUMP (Prosthetic Urology Multi-institutional Partnership), Barham, DW

Mayo Clinic

The Journal of Sexual Medicine | December 10, 2024 | Volume: 21 | Issue: Supplement_6 | Pages: No page available

10.1093/jsxmed/qdae161.121 Get It

Abstract Introduction Inflatable penile prosthesis (IPP) surgery is a well-established treatment for erectile dysfunction (ED). There is little information in the literature regarding the utilization of perioperative antimicrobial prophylaxis in primary and revision IPP surgeries. Objective We investigated the patterns of perioperative antimicrobial prophylaxis among a large multinational cohort of primary and revision IPP surgeries. Methods We conducted a retrospective analysis of 5400 patients (4187 primary IPP patients and 849 revision IPP patients) from our Prosthetic Urology Multi-Institutional Partnership (PUMP) institutions. Usage data for intravenous (IV), preoperative oral, and postoperative oral antimicrobials were analyzed. We specifically assessed patient profiles, antimicrobial selection, and antimicrobial duration. Multivariate statistical analyses were conducted to identify significant variations between primary and revision surgeries. Results For patients undergoing primary IPP placement, 81.9% received IV antibiotics for &lt;24 hours whereas 18.1% received IV antibiotics for &gt;24 hours. Preoperative oral antimicrobials were used in 59.4% of patients and 99.4% received postoperative oral antimicrobials. The overall infection rate for primary implants was 2%. Notably, quinolone administration shows a higher postoperative infection rate (11.4%) compared to gentamicin (1.9%), cephalosporin (0%), and vancomycin (1.0%). Multivariable regression analysis identifies factors such as a history of infection, diabetes, and priapism as predictors for postoperative infections. Furthermore, the study finds that perioperative antifungal use is associated with a decreased risk of infection. Conclusions This study provides valuable insights into the patterns of perioperative antimicrobial prophylaxis. Duration, type, and route of antibiotics given preoperatively or postoperatively do not affect postoperative infection rates among high volume prosthetic urologists. Giving IV antibiotics for more than 24 hours does not affect postoperative infection. Perioperative antifungals are a protective factor. Disclosure Any of the authors act as a consultant, employee or shareholder of an industry for: Coloplast, Clarus Therapeutics, Antares Pharma, Acerus.
Feasibility of Multi-Modal Physical Function Data Collection to Assess Treatment Tolerability in Patients with Lymphoma
Bhatnagar, Vishal , Copley, Devin B, Diamond, Matthew, Faust, Louis , Power, Brad , Ritchie, Jessica , Ruddy, Kathryn J. , Tarver, Michelle E. , Torre, La, Gross, Cary P. , Thanarajasingam, Gita , Paludo, Jonas , Dueck, Amylou C. , Brown, Abbie Y, Cathcart-Rake, Elizabeth , Diamond, Matthew, Fiero, Mallorie H. , Huntington, Scott F. , Jeffery, Molly Moore , Jones, Lee W. , Noble, Brie N. , Ross, Joseph S. , Mougalian, Sarah S. , Torre, Lisa M, Wood, William A. , Kluetz, Paul Gustav

Mayo Clinic

Blood | December 5, 2024 | Volume: 144 | Issue: Supplement 1 | Pages: 387-387

10.1182/blood-2024-194607 Get It

Background: Physical function (PF) is an important outcome that can inform cancer treatment tolerability from a clinical and regulatory perspective. PF can be assessed through different modalities: patient-reported (PRO), clinician-reported (ClinRo), performance tests (PerfO), and digital sensors (wearables). No standard approach for PF measurement has been defined, and each modality bears unique implementation challenges. The Integrating 4 Measures to Assess Physical Function study (In4M, NCT05214144) characterized the performance of these PF modalities in patients receiving cytotoxic chemotherapy, with a goal of guiding an assessment strategy in future cancer trials. Here we present feasibility results of the In4M study in patients with lymphoma. Methods: In4M is a prospective observational study with longitudinal PF assessment of PROs, ClinRo, PerfO, and wearable sensor data for over 9 months in patients initiating chemotherapy for lymphoma or breast cancer at Mayo Clinic and Yale University. Patient-reported PF was assessed using several validated ePRO instruments, ClinRo utilized clinician-reported Eastern Cooperative Oncology Group (ECOG) performance status, PerfO was measured via 6-minute walk test (6MWT), and digital sensor data was obtained from a wearable (Fitbit) provided to all participants. We evaluated the feasibility of implementing these PF modalities through compliance outcomes and a study-specific exit survey. Descriptive statistics included medians and interquartile ranges (IQR) for continuous variables and frequencies for categorical variables. We used a mixed model to estimate mean number of Fitbit compliant days per week. Results: Among 66 patients with lymphoma in the study (median age was 57 years; 52% were male), 90% self-reported as White, 4.9% as Black, 1.6% as Asian, 1.6% as American Indian or Alaska Native, and 1.6% as multiple races. Ethnicity was reported as non-Hispanic/Latino by 93% of patients. Education status was reported as more than high school by 92% of patients, and 49% reported full-time employment at time of enrollment. The overall ePROs completion rate was 80.7% for the entire study period. Baseline ePRO completion rate was 93.9%. Completion rate while undergoing chemotherapy was 91.3% and 75.4% in the post-treatment follow-up. The median time to complete ePROs was 4.1 minutes (IQR 2.8-5.9), ranging from 3.1 minutes for surveys with 37 questions to 5.6 minutes for surveys with 55 questions (survey length varied by timepoint). The baseline 6MWT was completed by 91% of patients. The most common reasons for not completing the baseline 6MWT were: patient refusal (50%, 3/6), patient not physically present (33%, 2/6), and unable to complete due to fatigue (17%, 1/6). The 3-month 6MWT was completed by 66% (40/61) of patients, with the most common reasons for missingness being: patient not physically present (38%, 8/21) and unable to complete due to fatigue (14%, 3/21). When considering the days when Fitbit was used, the median wear time was 21.3 hours (IQR 18.9-22.5) per day. The proportion of compliant days (&gt;10 hours of wear time during waking hours) was 53% (IQR 20-84). The median of participants' average compliant days per week was 5.4 (IQR 4.3-6.1) days/week after enrollment, with a slight downward trend over time (-0.017 compliant days per week [95% CI: -0.021, -0.012, p &lt;0.001] over each consecutive week in the study). The exit survey was completed by 39 (59%) patients. Most participants (85%) indicated they did not find the ePRO surveys burdensome to complete. Using the Fitbit (charging and syncing) was found to be manageable by most patients (87% and 84%, respectively). 60.8% of patients did not find the wearable bothersome to use, while the main themes reported by the remaining patients were related to the operation of the wearable itself (functions, small text size, forgetting login information) or discomfort (band material, wearing at night). Conclusion: Multi-modal assessment of PF with PRO, ClinRo, PerfO and wearable sensor data in patients with lymphoma undergoing treatment is feasible. Designing lymphoma therapeutic trials that incorporate at least one PF assessment modality, or assessment with a parsimonious combination of modalities, is achievable and may yield valuable insights into treatment tolerability for clinical and regulatory purposes.
Atypical Teratoid Rhabdoid Tumor of the Brain in a Young Adult With Down Syndrome: Case Report and Literature Review
Judd, Dallin, Almefty, Kaith K. , Vern-Gross, T.Z., Hoffman, Lindsey M. , Abdullaev, Ziedulla , Quezado, Martha , Aldape, Kenneth , Tiwari, Nishant , Vaughn, Jennifer, Mangum, Ross , Vern-Gross, Tamara Z, Mangum, Ross

Mayo Clinic

Journal of Pediatric Hematology/Oncology | November 26, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mph.0000000000002977 | PMID 39589148 Get It

Atypical teratoid/rhabdoid tumor (ATRT) is an aggressive, malignant embryonal tumor with dismal long-term survival despite aggressive multimodal therapy. While this tumor typically presents in infancy or early childhood, there are published case reports of adult-onset ATRT. Making prognostic conclusions or therapeutic decisions for this older patient population remains challenging due to the paucity of these reports. A 25-year-old female with Down syndrome presented with dysphagia and facial droop and was found to have an avidly enhancing, cerebellopontine angle mass. Histology demonstrated sheets of rhabdoid cells with loss of INI1 expression, pathognomonic for ATRT. Further sequencing detected a frameshift SMARCB1 mutation and methylation profiling matched with high confidence to the MYC subclass of ATRT. The patient was treated with subtotal surgical resection and focal proton beam irradiation, followed by chemotherapy on a modified regimen due to concern for heightened risk of treatment-related toxicity. On most recent follow-up 22 months from diagnosis, the patient remains without evidence of disease. This report represents the first known case of ATRT in a young adult patient with Down syndrome, offering unique mechanistic insight into the tumorigenesis of ATRT. Further studies are needed to define an appropriate risk-adapted and standardized therapeutic approach for this patient population.
Neurofibroma-like Desmoplastic Melanoma
Gru, Alejandro A. , Guo, Ruifeng, Elias, Roy , Pallavajjala, Aparna, Gross, John , Gru, Alejandro , Baraban, Ezra G. , Dudley, Jonathan C.

Mayo Clinic

American Journal of Surgical Pathology | November 1, 2024 | Volume: 49 | Issue: 1 | Pages: 1-10

10.1097/pas.0000000000002327 | PMID 39484711 Get It

A subset of desmoplastic melanomas (DMs) can show extensive morphologic and immunohistochemical overlap with cutaneous diffuse-type neurofibroma. Neurofibroma-like desmoplastic melanoma (NFLDM) thus poses a significant diagnostic pitfall because the clinical implications of these 2 entities differ dramatically. A series of 17 DMs, including 5 cases of NFLDM, were compared with a cohort of 53 cutaneous diffuse-type neurofibromas to explore the utility of molecular testing in the differential diagnosis between NFLDM and neurofibroma and to determine potentially useful morphologic features in this differential diagnosis. Unlike NFLDM, cutaneous diffuse-type neurofibromas: (1) rarely feature intratumoral or peritumoral lymphoid aggregates, (2) consistently harbor an intrinsic stromal support vasculature composed of evenly spaced capillary-sized vessels, and (3) infiltrate adjacent adipose tissue in a dermatofibrosarcoma protuberans–like manner with a complete lack of chronic inflammation or fat necrosis at the leading edge of the tumor. Conversely, DMs, including NFLDM: (1) do not contain Wagner-Meissner bodies, (2) often induce fat necrosis and/or chronic inflammation at the interface with adjacent fibroadipose tissue, (3) lack the intrinsic capillary-sized stromal vasculature observed in most neurofibromas, and (4) may harbor foci of perineuriomatous differentiation, mimicking a hybrid nerve sheath tumor. Any deviation from the expected clinical or morphologic features of cutaneous diffuse-type neurofibroma should raise suspicion for NFLDM. Although not entirely sensitive or specific, molecular testing can help to support the diagnosis of NFLDM by demonstrating genetic abnormalities associated with melanoma, including a UV-light–induced mutational signature, high tumor mutational burden, and/or chromosomal copy number alterations typical of melanoma.
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Long, Jessica B., Sprenkle, Preston C. , Kim, Isaac Yi , Saperstein, Lawrence, Rabil, Maximilian , Ghaffar, Umar , Karnes, R. Jeffrey , Ma, Xiaomei, Gross, Cary P. , Kunst, Natalia , Westvold, Sarah J. , Wang, Shi‐Yi , Leapman, Michael

Mayo Clinic

JAMA Network Open | October 23, 2024 | Volume: 7 | Issue: 10 | Pages: e2440591

10.1001/jamanetworkopen.2024.40591 | PMID 39441595 Get It

ImportanceAlthough prostate-specific membrane antigen positron emission tomography (PSMA-PET) has shown improved sensitivity and specificity compared with conventional imaging for the detection of biochemical recurrent (BCR) prostate cancer, the long-term outcomes of a widespread shift in imaging are unknown.ObjectiveTo estimate long-term outcomes of integrating PSMA-PET into the staging pathway for recurrent prostate cancer.Design, Setting, and ParticipantsThis decision analytic modeling study simulated outcomes for patients with BCR following initial definitive local therapy. Inputs used were from the literature and a retrospective cohort study conducted at 2 institutions. The base case analysis assumed modest benefits of earlier detection and treatment, and scenario analyses considered prostate-specific antigen (PSA) level at imaging and different outcomes of earlier vs delayed treatment. The analysis was performed between April 1, 2023, and May 1, 2024.Exposures(1) Immediate PSMA-PET imaging, (2) conventional imaging (computed tomography and bone scan [CTBS]) followed by PSMA-PET if CTBS findings were negative or equivocal, and (3) CTBS alone.Main Outcomes and MeasuresThe main outcomes were detection of metastases, deaths from prostate cancer, and life-years and quality-adjusted life-years (QALYs) gained.ResultsThe model estimated that per 1000 simulated patients with BCR (assumed median age, 66 years), PSMA-PET is expected to diagnose 611 (95% uncertainty interval [UI], 565-656) patients with metastasis compared with 630 (95% UI, 586-675) patients diagnosed using CTBS followed by PSMA-PET and 297 (95% UI, 202-410) patients diagnosed using CTBS alone. Moreover, the estimated number of prostate cancer deaths was 512 (95% UI, 472-552 deaths) with PSMA-PET, 520 (95% UI, 480-559 deaths) with CTBS followed by PSMA-PET, and 587 (95% UI, 538-632 deaths) with CTBS alone. Imaging with PSMA-PET yielded the highest number of QALYs, which were 824 (95% UI, 698-885) higher than CTBS. These results differed by PSA level at the time of testing, with the highest incremental life-years and QALYs and lowest number of deaths from prostate cancer among patients with PSA levels of at least 5.0 ng/mL. Finally, the estimates were sensitive to the expected benefit of initiating therapy for recurrent prostate cancer earlier in the disease course.Conclusions and RelevanceThe results of this decision-analytic model suggest that upfront PSMA-PET imaging for the evaluation of BCR is expected to be associated with reduced cancer mortality and gains in life-years and QALYs compared with the conventional imaging strategy, assuming modest benefits of earlier detection and treatment.